Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Rating of “Buy” from Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has received an average rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $54.20.

A number of research analysts recently issued reports on the company. The Goldman Sachs Group lifted their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC lifted its position in shares of Tarsus Pharmaceuticals by 16.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company’s stock worth $6,924,000 after buying an additional 29,465 shares during the last quarter. Creative Planning purchased a new stake in Tarsus Pharmaceuticals in the third quarter valued at $362,000. Vestal Point Capital LP purchased a new stake in Tarsus Pharmaceuticals in the third quarter valued at $7,565,000. Essex Investment Management Co. LLC acquired a new position in Tarsus Pharmaceuticals in the third quarter valued at $3,590,000. Finally, Verition Fund Management LLC purchased a new position in shares of Tarsus Pharmaceuticals during the third quarter worth about $763,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock opened at $55.00 on Tuesday. The firm has a 50 day moving average of $48.24 and a two-hundred day moving average of $35.80. The stock has a market capitalization of $2.10 billion, a PE ratio of -14.44 and a beta of 1.04. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a 52 week low of $18.99 and a 52 week high of $56.77.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.